Home › Pulmonary Hypertension › NCT06299436

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

Who can join

Ages 18 to 90 · All sexes

Inclusion Criteria:

* Adult patients aged between 18 and 90 years of age
* Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40-50%)
* Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure

Exclusion Criteria:

* Unable to interrupt VKA anticoagulation
* Point of care International Normalized Ratio (INR) \> 1.5
* Pregnant patients
* Acute hospitalization or decompensation within 2 weeks prior to study date
* Participation in a study involving an investigational drug within 4 weeks prior to study date
* Inability to lie flat in the supine position
* Symptomatic hemodynamic instability at rest or during the procedure

About the study

Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.

Sponsor: Johns Hopkins University · Participants: 50 · Started: Dec 10, 2024

Contact the study team

• Steven Hsu, MD · Phone: 410-502-0955

Official record on ClinicalTrials.gov — NCT06299436

Locations in the U.S.

Conditions

• Pulmonary Hypertension
• Heart Failure
• Cardiomyopathy

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.